Who are EU-approved Xolair's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Omalizumab Injection, Omalizumab (Xolair), ANTI-IGE THERAPY (XOLAIR), Xolair injections, Omalizumab (CinnaGen).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/eu-approved-xolair.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

EU-approved Xolair — Competitive Intelligence Brief

EU-approved Xolair (EU-approved Xolair) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: IgE monoclonal antibody. Area: Immunology / Allergy.

phase 3 IgE monoclonal antibody Immunoglobulin E (IgE) Immunology / Allergy Biologic Live · refreshed every 30 min

Target snapshot

EU-approved Xolair (EU-approved Xolair) — Celltrion. Xolair is a monoclonal antibody that binds to immunoglobulin E (IgE) and prevents its interaction with high-affinity IgE receptors on mast cells and basophils, thereby reducing allergic cascade activation.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
EU-approved Xolair TARGET	EU-approved Xolair	Celltrion	phase 3	IgE monoclonal antibody	Immunoglobulin E (IgE)
Omalizumab Injection	Omalizumab Injection	Rigshospitalet, Denmark	marketed	IgE monoclonal antibody	Immunoglobulin E (IgE)
Omalizumab (Xolair)	Omalizumab (Xolair)	McMaster University	marketed	IgE monoclonal antibody	Immunoglobulin E (IgE)
ANTI-IGE THERAPY (XOLAIR)	ANTI-IGE THERAPY (XOLAIR)	Children's Hospital of The King's Daughters	marketed	Anti-IgE monoclonal antibody	Immunoglobulin E (IgE)
Xolair injections	Xolair injections	University of California, Los Angeles	marketed	Anti-IgE monoclonal antibody	Immunoglobulin E (IgE)
Omalizumab (CinnaGen)	Omalizumab (CinnaGen)	Cinnagen	phase 3	IgE monoclonal antibody	Immunoglobulin E (IgE)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (IgE monoclonal antibody class)

Celltrion · 1 drug in this class
Cinnagen · 1 drug in this class
McMaster University · 1 drug in this class
Rigshospitalet, Denmark · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). EU-approved Xolair — Competitive Intelligence Brief. https://druglandscape.com/ci/eu-approved-xolair. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab